ArticleScientific reports2017
Thoracic radiotherapy (TRT) improved survival in both oligo- and polymetastatic extensive stage small cell lung cancer.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Efficacy and safety of tyrosine kinase inhibitors with thoracic radiotherapy for patients with oncogene-mutated non-small cell lung cancer: a meta-analysis.Radiation oncology (London, England) · 2024Pooled it
- Role of Local Treatment for Oligometastasis: A Comparability-Based Meta-Analysis.Cancer research and treatment · 2022Pooled it
- Efficacy and safety of thoracic radiotherapy for extensive stage small cell lung cancer after immunotherapy in real world.Clinical & experimental metastasis · 2023Trial
- Clinical outcomes of thoracic radiotherapy in combination with chemoimmunotherapy in elderly patients with extensive-stage small cell lung cancer.Precision radiation oncology · 2026Article
- Consolidation thoracic radiotherapy after chemoimmunotherapy provides survival benefit in elderly patients with extensive-stage small-cell lung cancer: a multicenter study.Therapeutic advances in medical oncology · 2026Article
- Extended Follow-Up Analysis of First-Line Atezolizumab in Extensive-Stage Small Cell Lung Cancer: A Real-World Multicenter Prospective Cohort Study.Thoracic cancer · 2025Observational
- Role of radiotherapy in extensive-stage small cell lung cancer after durvalumab-based immunochemotherapy: A retrospective study.Chinese medical journal · 2025Article
- [Advances in Radiotherapy for Extensive-stage Small Cell Lung Cancer in the Era of Immunotherapy].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025Review
- Synchronous Oligometastasis and Oligoprogression as a Prognostic Marker in Patients With Extensive-Stage SCLC Treated With a Combination of Immune-Checkpoint Inhibitor and Chemotherapy (HOT2301).JTO clinical and research reports · 2024Article
- Stereotactic body radiotherapy for extra-cranial oligoprogressive or oligorecurrent small-cell lung cancer.Clinical and translational radiation oncology · 2023Article
- Article
- Small cell lung cancer with thyroid gland oligometastasis: A case report.Thoracic cancer · 2021Article
- Role of thoracic radiotherapy in extensive stage small cell lung cancer: a systemic review and meta-analysis.Annals of translational medicine · 2021Article
- Benefits of local consolidative treatment in oligometastases of solid cancers: a stepwise-hierarchical pooled analysis and systematic review.NPJ precision oncology · 2021Article
- Consolidation radiotherapy for patients with extended disease small cell lung cancer in a single tertiary institution: impact of dose and perspectives in the era of immunotherapy.Radiology and oncology · 2020Article
- Oligometastatic Breast Cancer: Is This a Curable Entity? A Contemporary Review of the Literature.Current oncology reports · 2020Review
- Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype.Endocrine connections · 2019Article
- Thoracic Radiotherapy Benefits Elderly Extensive-Stage Small Cell Lung Cancer Patients with Distant Metastasis.Cancer management and research · 2019Article
- Dose escalation and associated predictors of survival with consolidative thoracic radiotherapy in extensive stage small cell lung cancer (SCLC): A National Cancer Database (NCDB) propensity-matched analysis.Lung cancer (Amsterdam, Netherlands) · 2018Article
- Radiotherapy improves the survival of patients with extensive-disease small-cell lung cancer: a propensity score matched analysis of Surveillance, Epidemiology, and End Results database.Cancer management and research · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There has been no previous study on the efficacy of the thoracic radiotherapy (TRT) in oligometastatic or polymetastatic extensive stage small-cell lung cancer (ES-SCLC) to the overall survival (OS). In a group of 270 ES-SCLC cases retrospective study, 78 patients (28.9%) had oligometastases and 192 (71.1%) had polymetastases, among which 51 oligometastatic patients (65.4%) and 93 polymetastatic patients (51.6%) received TRT. Propensity score matching (PSM) was utilized. The 2-year OS, progression free survival (PFS) and local control (LC) in oligometastatic and polymetastatic patients were 22.8% and 4.5% (p < 0.001), 12.0% and 3.8% (p < 0.001), and 36.7% and 6.1% (p < 0.001), respectively. The 2-year OS in oligometastatic patients with the chemotherapy + radiotherapy and chemotherapy alone were 25.2% and 12.7% (p = 0.002), in contrast to 10.0% and 6.8% (p = 0.030) in polymetastatic patients. The estimated hazard ratios for survival were 2.9 and 1.7 for both oligometastatic and polymetastatic patients with radiotherapy. The polymetastatic group has a lower LC (6.1% v.s. 36.7%, (p < 0.001)), due to polymetastases patients receiving involved-sites radiotherapy with low dose schemas. TRT improved OS of patients with oligometastases and polymetastases. Our study demonstrated that aggressive TRT might be a suitable addition of chemotherapy when treating ES-SCLC patients with oligometastases and polymetastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.